First-in-Human, First-in-Class Phase I Trial of the Anti-CD47 Antibody Hu5F9-G4 in Patients With Advanced CancersBranimir I. Šikić, Sukhmani K. Padda, Matthew Axt et al.|Journal of Clinical Oncology|2019Cited by 590
Disrupting the CD47-SIRPα anti-phagocytic axis by a humanized anti-CD47 antibody is an efficacious treatment for malignant pediatric brain tumorsSamuel Cheshier, Siddhartha S. Mitra, Abdullah H. Feroze et al.|Science Translational Medicine|2017Cited by 427
Antibody therapy targeting the CD47 protein is effective in a model of aggressive metastatic leiomyosarcomaBadreddin Edris, Matt van de Rijn, Kipp Weiskopf et al.|Proceedings of the National Academy of Sciences|2012Cited by 256
Dysregulated Lipid Synthesis by Oncogenic IDH1 Mutation Is a Targetable Synthetic Lethal VulnerabilityDanièl Thomas, Ravindra Majeti|Cancer Discovery|2022Cited by 59
Genome engineering with Cas9 and AAV repair templates generates frequent concatemeric insertions of viral vectorsFabian P. Suchy, Hiromitsu Nakauchi, Daiki Karigane et al.|Nature Biotechnology|2024Cited by 56